Decoding Brain Metastases: New Genetic Insights Offer Hope for Cancer Care
A comprehensive genetic study analyzing over 150,000 tumor samples reveals key insights into brain metastases, highlighting high mutational burden and shared pathways.
Understanding how cancer spreads to the brain remains one of the most complex challenges in modern oncology. While treatments successfully control the disease in other parts of the body, brain metastases often continue to advance. A recent comprehensive study, published in the journal Neuro-Oncology in collaboration with the American company Foundation Medicine, sheds new light on the genetic landscape of brain metastases.
Analyzing Thousands of Tumor Samples
The research team analyzed more than 150,000 tumor samples, including approximately 4,500 brain metastases. Across each sample, about 450 cancer-related genes were sequenced. Researchers compared the genetic profiles of brain metastases with primary tumors and metastases in other organs across six major cancer types: non-small cell lung cancer, breast cancer, melanoma, colorectal cancer, esophageal cancer, and neuroendocrine tumors.
The findings revealed that in all six cancer types, the proportion of tumors with a high tumor mutational burden (TMB) was significantly greater in brain metastases compared to primary tumors and metastases in other organs. This phenomenon was especially prominent in lung cancer and melanoma.
A Common Genetic Pathway
When examining individual genes, researchers found distinct differences between cancer types. However, analyzing functional gene networks revealed a striking commonality. In five of the six cancer types, brain metastases showed an increased number of alterations in the ERK-MAPK pathway, which helps cells process external signals, grow, and survive.
"This research does not provide an immediate cure, but it outlines a broad and detailed genetic map of brain metastases on an unprecedented scale," noted the study leaders, Prof. Ido Wolf and Prof. Tami Rubinek from the Tel Aviv Sourasky Medical Center (Ichilov).
The study provides a crucial foundational infrastructure for researchers worldwide, enabling more targeted experimental designs and pointing toward potential vulnerabilities in metastatic cells.
